Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GPR183 | P32249 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ME2 | P23368 | 1/20 | 0.55 |
| ▸ | ME1 | P48163 | 1/20 | 0.55 |
| ▸ | ME3 | Q16798 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702458 | 0.85 | KMT2A (0.62) | ENPP2MAPTMEN1GPR183KMT2A | |
| SCHEMBL7168690 | 0.81 | HSD11B1 (0.62) | MAPTNPSR1MEN1KMT2ALMNA | |
| SCHEMBL2471006 | 0.80 | MAPT (0.75) | MAPTNPSR1MEN1KMT2AHTT | |
| SCHEMBL2473451 | 0.80 | MEN1 (0.59) | ENPP2MAPTMEN1GPR183KMT2A | |
| SCHEMBL2472473 | 0.77 | MAPT (0.56) | MAPTNPSR1MEN1KMT2ALMNA | |
| SCHEMBL2468545 | 0.77 | ALDH1A1 (0.66) | MAPTMEN1GPR183KMT2ALMNA | |
| SCHEMBL2469559 | 0.77 | MEN1 (0.55) | ENPP2MAPTMEN1GPR183KMT2A | |
| SCHEMBL2702559 | 0.76 | KMT2A (0.68) | MEN1KMT2ALMNAMAPK1POLB | |
| SCHEMBL2469030 | 0.76 | MEN1 (0.49) | ENPP2MAPTMEN1GPR183KMT2A | |
| SCHEMBL27979662 | 0.76 | POLB (0.84) | ENPP2MAPTMEN1GPR183KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | claimed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | ENPP2 1608/4885MAPT 3715/4885NPSR1 2596/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | ENPP2 1608/4885MAPT 3715/4885NPSR1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.